Phase 3 Thyroid Cancer Trial, Recruiting NCT07383246 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Thyroid Cancer
Back to Thyroid Cancer

Phase 3 Thyroid Cancer Trial, Recruiting

NCT07383246
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been newly diagnosed with medullary thyroid carcinoma, confirmed either by a lab test of tissue or cells, OR by a blood test showing a raised calcitonin level (above 10 pg/mL) where other infections or tumour-related causes have been ruled out
  • Your doctors expect you to live for at least 12 weeks or more
  • You are generally well enough to carry out light activity or normal daily tasks (your doctor can confirm this based on a standard fitness scale)
  • Scans have shown the cancer has not spread to distant parts of the body, and the affected area can be removed with surgery
  • You are planned to have surgery within the next 30 days
  • If you are a woman who could become pregnant, you agree to use reliable contraception during the study and for 6 months afterwards; male participants must also agree to use contraception during this period
  • You are able to understand what the trial involves, are willing to take part, and can sign a consent form

Who may not be able to join:

  • You have already had any treatment for medullary thyroid carcinoma, such as surgery, radiotherapy, targeted therapy, or other procedures
  • Your blood tests show that your bone marrow, liver, or kidneys are not working well enough (confirm specific blood test thresholds with the trial site)
  • You are pregnant, planning to become pregnant, or currently breastfeeding
  • You have a history of any other type of cancer
  • You are unable to lie flat and still for at least 30 minutes
  • You have a known allergy to contrast dye used in scans
  • You have claustrophobia or a mental health condition that may make it difficult to follow the study procedures
  • You are unwilling to take part in the trial
  • Your doctors do not consider you suitable for surgery, or you are not willing to have surgery
  • Your doctor feels there is any other reason you would not be suitable for this study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Shaoyan Liu, MD, Chinese Academy of Medical Sciences

Phone: 0086-18500487274

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
25 August 2025
Est. completion
1 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Biochemical cure rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov